[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urolithiasis-calcium-oxalate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urolithiasis-calcium-oxalate":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,72,88,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":37,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100592122","endogenous-oxalate-synthesis-in-idiopathic-calcium-oxalate-kidney-stone-disease-100592122",false,"NCT06989320","Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease","Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Formers","Inclusion Criteria:\n\n* age 18-80 yrs\n* Body Mass Index \\> 18.5 kg\u002Fm2\n* Normal fasting serum electrolytes on comprehensive metabolic profile\n* Willing to ingest fixed diets\n* Willing to stop supplements (vitamins including vitamin C, calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during study.\n* For stone formers: first time or recurrent Calcium Oxalate stone former. Composition of most recent stone ≥ 50% calcium oxalate if available, uric acid component \\\u003C20%\n\nExclusion Criteria:\n\n* Chronic Kidney Disease stage 4-5\n* Primary hyperoxaluria, Enteric (secondary) hyperoxaluria\n* Liver, bowel, endocrine or renal diseases (other than idiopathic Calcium Oxalate kidney stones) or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: Cystic fibrosis, Celiac disease, Cystinuria, Uric acid stone former, Nephrotic syndrome, Sarcoidosis, Renal tubular acidosis, Primary hyperparathyroidism, Neurogenic bladder, Urinary diversion, Chronic diarrhea, Bariatric surgery, Inflammatory bowel disease\n* Pregnancy or breast-feeding\n* Incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus\n* Active malignancy or treatment for malignancy within 12 months prior to screening\n* Utilization of immunosuppressive medication\n* Uncontrolled hypertension or diabetes\n* Diabetes type 1",true,"ALL","18 Years","80 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased production of oxalate by the body, which would lead to increased urinary excretion of oxalate.\n\nThe study will recruit adult patients with a history of calcium oxalate kidney stones and healthy volunteers without kidney stones.\n\nParticipants will\n\ningest fixed diets containing low amounts of oxalate for 5 days ingest a soluble form of glycolate and vitamin C collect urine, blood, stool during the dietary and oral dosing portions of the study and also collect breath sample during the oral glycolate test",[28,29,30,31,32,33,34,35,36],"Kidney Stones","Kidney Calculi","Urolithiasis","Urolithiasis, Calcium Oxalate","Nephrolithiasis","Nephrolithiasis, Calcium Oxalate","Oxalate Urolithiasis","Healthy","Healthy Volunteer",[38],"oxalate synthesis","RECRUITING","2026-05-27",{"date":42,"type":43},"2026-05-29","ACTUAL",{"date":45,"type":43},"2025-05-27",{"date":47,"type":22},"2031-12-31",{"name":49,"class":50},"University of Alabama at Birmingham","OTHER",2,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":71,"locationsCount":51},"100541567","gut-oxalate-absorption-in-calcium-oxalate-stone-disease-100541567","NCT06331546","Gut Oxalate Absorption in Calcium Oxalate Stone Disease","Gastrointestinal Oxalate Absorption in Calcium Oxalate Stone Disease","Inclusion Criteria:\n\n* age 18-70 yrs\n* Body Mass Index \\> 18.5 kg\u002Fm2\n* Normal fasting serum electrolytes on comprehensive metabolic profile\n* Willing to ingest fixed diets\n* Willing to stop supplements (vitamins including vitamin C, calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during study.\n* For stone formers: first time or recurrent Calcium Oxalate stone former. Composition of most recent stone ≥ 50% calcium oxalate if available, uric acid component \\\u003C20%\n\nExclusion Criteria:\n\n* Chronic Kidney Disease stage 4-5\n* Primary hyperoxaluria, Enteric (secondary) hyperoxaluria\n* Liver, bowel, endocrine or renal diseases (other than idiopathic Calcium Oxalate kidney stones) or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: Cystic fibrosis, Celiac disease, Cystinuria, Uric acid stone former, Nephrotic syndrome, Sarcoidosis, Renal tubular acidosis, Primary hyperparathyroidism, Neurogenic bladder, Urinary diversion, Chronic diarrhea, Bariatric surgery, Inflammatory bowel disease\n* Pregnancy or breast-feeding\n* Incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus\n* Active malignancy or treatment for malignancy within 12 months prior to screening\n* Utilization of immunosuppressive medication\n* Uncontrolled hypertension or diabetes\n* Diabetes type 1\n* Chronic NSAID use","70 Years",{"count":21,"type":22},[25],"The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased absorption of dietary oxalate, which would lead to increased urinary excretion of oxalate.\n\nThe study will recruit adult patients with a history of calcium oxalate kidney stones and healthy volunteers without kidney stones.\n\nParticipants will\n\n* ingest fixed diets containing low and moderately high amounts of oxalate for 5 days at a time\n* ingest a soluble form of oxalate and sugar preparations to test gut permeability\n* collect urine, blood, stool and breath sample during the fixed diets and the soluble oxalate test",[64,29,30,31,32,33,34,65,35],"Kidney Stone","Oxaluria",{"date":67,"type":43},"2026-05-28",{"date":69,"type":43},"2024-04-17",{"date":47,"type":22},{"name":49,"class":50},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":87,"locationsCount":51},"100541467","o-formigenes-colonization-in-calcium-oxalate-kidney-stone-disease-100541467","NCT06330246","O. Formigenes Colonization in Calcium Oxalate Kidney Stone Disease","Oxalobacter Formigenes Colonization in Calcium Oxalate Kidney Stone Formers","Inclusion Criteria\n\n* age 19-70 yrs\n* Body Mass Index \\> 18.5 kg\u002Fm2\n* First time or recurrent Calcium Oxalate stone former. Composition of most recent stone ≥ 50% calcium oxalate if available\n* Not colonized with Oxalobacter formigenes\n* Normal fasting serum electrolytes on comprehensive metabolic profile\n* Willing to ingest fixed diets\n* Willing to stop supplements (vitamins including vitamin C, calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during fixed diet phases.\n* If on medications for stone prevention (e.g. thiazides, citrate, allopurinol), stable dose regimen for at least 2 weeks prior to and during study\n\nExclusion Criteria\n\n* Chronic Kidney Disease stage 4-5\n* Primary hyperoxaluria\n* Liver, endocrine or renal diseases (other than idiopathic Calcium Oxalate kidney stones) or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: Cystic fibrosis, Cystinuria, Uric acid stone former, Nephrotic syndrome, Sarcoidosis, Renal tubular acidosis, Primary hyperparathyroidism, Neurogenic bladder, Urinary diversion\n* Pregnancy or breast-feeding\n* Incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus\n* Active malignancy or treatment for malignancy within 12 months prior to screening\n* Utilization of immunosuppressive medication\n* Uncontrolled Hypertension or diabetes\n* Diabetes type 1\n* Current Colonization with Oxalobacter formigenes",{"count":80,"type":22},40,[25],"The goal of this trial is to test if colonization with the gut bacteria Oxalobacter formigenes leads to a reduction in urinary oxalate excretion in patients with calcium oxalate kidney stone disease.\n\nThe study will recruit adult participants with a history of calcium oxalate kidney stones who are not colonized with Oxalobacter formigenes.\n\nParticipants will\n\n* ingest fixed diets containing low and moderately high amounts of oxalate for 4 days at a time\n* collect urine, blood and stool samples during the fixed diets\n* ingest a preparation of live Oxalobacter formigenes to induce colonization with Oxalobacter formigenes",[64,29,30,31,32,33,34,65],{"date":67,"type":43},{"date":69,"type":43},{"date":47,"type":22},{"name":49,"class":50},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100598473","a-single-center-clinical-study-on-the-efficacy-and-safety-of-visor-100598473","NCT07071948","A Single-Center Clinical Study on the Efficacy and Safety of VISOR","A Single-Center Clinical Study on the Efficacy and Safety of Vortex Intelligence Stone Optimized Removal (VISOR)","Inclusion Criteria:\n\n1. Patients with upper urinary tract calculi, where the maximum diameter of a single calculus or the cumulative diameter of multiple calculi is 1-3 cm\n2. Patients who choose to undergo \"flexible ureteroscopic holmium laser lithotripsy\"\n3. Aged 18-80 years, regardless of gender\n4. Subjects without mental illness or language dysfunction, who can understand the details of this study and sign the informed consent form\n\nExclusion Criteria:\n\n1. Patients with ureteral stricture or a history of ureteral stricture\n2. Patients with a history of open renal and\u002For ureteral surgery or laparoscopic surgery\n3. Fever (body temperature ≥ 38℃) due to urinary tract infection or other reasons within one week before surgery\n4. Pregnant women, lactating women, or women who are in the menstrual period\n5. ASA classification \\> Grade 3: patients with severe systemic diseases, heart diseases, pulmonary insufficiency, and failure of important organ functions, etc., who cannot tolerate anesthesia or surgery\n6. Patients with anatomical malformations such as polycystic kidney, horseshoe kidney, and ectopic kidney\n7. Patients with abnormal coagulation function (e.g., international normalized ratio (INR) \\> 1.5 or platelet count \\\u003C 80 × 10⁹\u002FL)\n8. Patients with failed sheath placement during surgery",{"count":96,"type":22},20,[25],"Goal of this trial:\n\nTo test a new tool called VISOR in adults (aged 18-80) with 1-3 cm kidney or ureter stones. We want to see:\n\n1. If it's safe and works well\n2. If its built-in features (flushing\u002Fsuction, pressure control, and stone-breaking\u002Fremoval) help clear stones better while keeping surgery safe.\n\nMain questions:\n\n1. Can the VISOR clear stones successfully (with fragments \\\u003C4 mm left) for at least 9 out of every 10 people within 24 hours after surgery?\n2. Will serious problems (like severe infections or ureteral injuries) happen to no more than 1 in 20 people (5%)?\n3. Can the device keep pressure inside the kidney below 30 mmHg (a safe level) during the entire surgery?\n\nWhat participants will do:\n\nHave stone removal surgery using VISOR (breaks and removes stones at the same time).\n\nGet a CT scan within 24 hours after surgery to check if stones are cleared.\n\nReturn 4 weeks (±1 week) after surgery for:\n\nAn imaging test (CT or ultrasound)\n\nA check for any health problems related to the surgery.",[31,64],[101,102,103,104],"urolithiasis","kidney stone","stone free rate","VISOR","2025-09-22",{"date":107,"type":43},"2025-09-26",{"date":109,"type":43},"2025-08-06",{"date":111,"type":22},"2027-02-28",{"name":113,"class":50},"Second Affiliated Hospital, School of Medicine, Zhejiang University",1,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":104,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":130,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100606915","clinical-trial-of-visor-vs-furs-for-upper-urinary-tract-stone-100606915","NCT07181759","Clinical Trial of VISOR vs fURS for Upper Urinary Tract Stone","Prospective Randomized Controlled Clinical Trial on the Treatment of Upper Urinary Tract Stones With VISOR and fURS","Inclusion Criteria:\n\n* Patients with upper urinary tract stones and a cumulative stone diameter ≤3 cm;\n* Patients scheduled to undergo \"flexible ureteroscopic holmium laser lithotripsy\";\n* Age ≥18 years;\n* Patients without psychiatric disorders or language dysfunction, capable of understanding the study and providing informed consent.\n\nExclusion Criteria:\n\n* Patients requiring bilateral lithotripsy in a single-stage ureteroscopic procedure;\n* Ipsilateral hydronephrosis with \\>4 cm renal pelvic separation;\n* Patients with a history of open or laparoscopic renal and\u002For ureteral surgery;\n* Fever (body temperature ≥38°C) due to urinary tract infection or other causes within one week prior to surgery;\n* Pregnant women;\n* Patients with severe systemic diseases, cardiac diseases, pulmonary insufficiency, or vital organ failure unable to tolerate anesthesia or surgery (ASA score ≥3);\n* Patients with anatomical abnormalities such as polycystic kidney, horseshoe kidney, or ectopic kidney;\n* Patients with coagulation disorders (e.g., INR \\>2.0 or platelet count \\\u003C80×10⁹\u002FL);\n* Patients currently participating in other device or drug clinical trials;\n* Patients deemed ineligible for the trial by the investigator.",{"count":123,"type":22},100,[25],"This prospective randomized controlled clinical study aims to evaluate the safety and efficacy of a novel Vortex Intelligence Stone Optimized Removal (VISOR,The experimental group) system compared to a single-use ureterorenoscope (the control) for treating upper urinary tract stones.\n\nA total of 100 patients with upper urinary tract stones (cumulative stone diameter ≤3 cm) will be enrolled and randomly assigned in a 1:1 ratio to either the experimental group (n=50) or the control group (n=50). The experimental group will undergo surgery using the innovative system, which integrates irrigation-suction, pressure monitoring-regulation, and lithotripsy-evacuation functions. The control group will be treated with a conventional single-use ureterorenoscope.\n\nThe primary outcome measure is the immediate stone-free rate (SFR), defined as the proportion of patients with residual fragments \\\u003C4 mm on renal non-contrast computed tomography (NCCT) performed within 24 hours postoperatively. Key secondary endpoints include the SFR at 3 months, operative and lithotripsy times, total laser energy used, intraoperative ureteral injury (Traxer grading), postoperative pain scores, incidence of fever (\\>38.0°C), and overall complication rates (Clavien-Dindo classification).\n\nPatient follow-up assessments will be conducted at 24 hours, 21±7 days, and 90±14 days post-surgery to monitor stone clearance, complications, and recovery. This study seeks to determine if the novel system offers superior stone clearance while maintaining a safe renal pelvic pressure profile, potentially improving outcomes for patients with larger renal stones treated ureteroscopically.",[31,127,128,129],"Ureteroscopy","Therapeutic Irrigation","Intraoperative Complications",[131,132,133,134,135,104,136],"Ureterorenoscopy","Upper urinary tract calculi","Intrarenal pressure","Stone-free rate (SFR)","Lithotripsy","Vortex intelligence Stone Optimized Removal(VISOR）","NOT_YET_RECRUITING","2025-09-12",{"date":140,"type":43},"2025-09-18",{"date":142,"type":22},"2025-09-20",{"date":144,"type":22},"2026-12-31",{"name":146,"class":50},"Ningbo No. 1 Hospital"]